GlassScriptPhysician profile
Garmen A Woo
NPI 1144551979
$34,755.78
in general payments reported to CMS, 2019-2025
28 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $220 · 2021: $781 · 2022: $684 · 2023: $2,590 · 2024: $11K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $8,892 · Travel and Lodging: $86.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,015.00 |
| Food and Beverage | $8,892.21 |
| Travel and Lodging | $86.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,833.04 | 2020-2025 | Mavyret, Creon |
| Gilead Sciences, INC. | $12,168.27 | 2019-2025 | Vemlidy |
| Novo Nordisk INC | $910.25 | 2022-2025 | Wegovy |
| Madrigal Pharmaceuticals | $683.99 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $636.81 | 2024-2025 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $480.94 | 2024-2025 | Saphnelo, Imfinzi |
| Amgen INC. | $460.98 | 2021-2024 | Otezla, Kyprolis |
| Genentech USA, INC. | $424.97 | 2022-2023 | Lunsumio, Evrysdi |
| Genzyme Corporation | $354.29 | 2023-2025 | |
| Lilly USA, LLC | $245.00 | 2023-2024 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $229.37 | 2024 | Ajovy, Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $215.25 | 2024 | |
| Janssen Scientific Affairs, LLC | $195.88 | 2023-2024 | |
| Terumo Medical Corporation | $178.68 | 2024 | Azur Cx Detachable |
| Ipsen Biopharmaceuticals, INC | $169.38 | 2024-2025 | Bylvay, Iqirvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $149.99 | 2024 | Invega, Invega Sustenna |
| Mallinckrodt Hospital Products INC. | $149.79 | 2024 | Terlivaz |
| Abbott Laboratories | $138.89 | 2023 | Freestyle Libre 3 |
| Pharmacosmos Therapeutics INC. | $129.27 | 2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $123.74 | 2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $123.02 | 2019 | |
| Karyopharm Therapeutics INC. | $122.27 | 2025 | Xpovio |
| Redhill Biopharma INC. | $117.99 | 2021 | |
| Genentech, INC. | $117.95 | 2022 | |
| Fresenius Kabi USA, LLC | $110.89 | 2024 | Smoflipid |
| Sanofi-Aventis U.S. LLC | $99.50 | 2023 | |
| Biogen, INC. | $95.79 | 2022 | |
| Cequr Corporation | $89.59 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garmen Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.